Durable Goods (Jun F) -9.4% vs 9.3% Prior, Ex-Trans 0.2% vs 0.2%
LONDON - ImmuPharma PLC (LSE:IMM), a specialist in drug discovery and development, has acknowledged the recent volatility in its share price. The company, which is focused on creating innovative treatments for autoimmune diseases, attributed the movements to its announcement on January 9, 2025, regarding significant advancements in its preclinical research program.
The research, conducted by ImmuPharma Biotech, the company's R&D subsidiary, has provided new insights into the mechanisms of autoimmune diseases, particularly focusing on P140, a peptide with potential applications in personalized medicine for conditions such as Systemic Lupus Erythematosus (SLE).
ImmuPharma's presence at the JP Morgan and Biotech Showcase healthcare conferences earlier in January also contributed to the heightened interest in the company. During these events, ImmuPharma engaged in ongoing discussions with several global BioPharma companies that have shown interest in P140 and its novel approach to treating autoimmune diseases.
Despite the share price movements, ImmuPharma has stated that there are no further material commercial or operational reasons behind the fluctuations. The company has committed to keeping the market informed of any significant commercial and scientific developments as they arise.
The company's announcement comes in response to the observed share price movements and aims to provide clarity to its shareholders and the market. Information in this article is based on a press release statement from ImmuPharma PLC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.